NASDAQ Stocks
· May 18, 2025 11:30 AM EDT
Not market news
Intellia Therapeutics Reports Two-Year Data Showing Sustained Reductions in TTR Levels and Positive Outcomes for ATTRv-PN Patients Following Nex-z Treatment
Intellia reports positive two-year results for nex-z, showing significant TTR reductions and improved ATTRv-PN outcomes without new safety concerns.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- NTLAIntellia Therapeutics Named
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
